Toxicities associated with hyperthermic isolated limb perfusion and isolated limb infusion in the treatment of melanoma and sarcoma (Q37130257)

18 August 2017

1 reference

title

Toxicities associated with hyperthermic isolated limb perfusion and isolated limb infusion in the treatment of melanoma and sarcoma (English)

1 reference

18 August 2017

Mecker G Möller

1

1 reference

18 August 2017

James M Lewis

series ordinal

2

1 reference

18 August 2017

Sophie Dessureault

series ordinal

3

1 reference

18 August 2017

Jonathan S Zager

series ordinal

4

1 reference

18 August 2017

publication date

1 May 2008

1 reference

International Journal of Hyperthermia

18 August 2017

published in

1 reference

18 August 2017

volume

24

1 reference

18 August 2017

issue

3

1 reference

18 August 2017

page(s)

275-289

1 reference

The role of isolated limb perfusion for melanoma confined to the extremities

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080/02656730701805520

Prognostic variables in recurrent limb melanoma treated with hyperthermic antiblastic perfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02656730701805520

Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02656730701805520

Toxicity and morbidity of isolated limb perfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02656730701805520

Thirty-five years of isolated limb perfusion for melanoma: indications and results

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02656730701805520

Systemic leakage and side effects of tumor necrosis factor alpha administered via isolated limb perfusion can be manipulated by flow rate adjustment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02656730701805520

Isolated limb infusion with cytotoxic agents: A simple alternative to isolated limb perfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02656730701805520

Isolated limb infusion for melanoma: a simple but effective alternative to isolated limb perfusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02656730701805520

Solitary and multiple isolated metastases of clear cell renal carcinoma to the pancreas: an indication for pancreatic surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02656730701805520

A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02656730701805520

Isolated limb infusion with fotemustine after dacarbazine chemosensitisation for inoperable loco-regional melanoma recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02656730701805520

Systemic and pulmonary circulatory effects of protamine following cardiopulmonary bypass in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02656730701805520

Long-term locoregional vascular morbidity after isolated limb perfusion and external-beam radiotherapy for soft tissue sarcoma of the extremity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02656730701805520

Predictors of outcome after hyperthermic isolated limb perfusion: role of tumor response

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02656730701805520

In-transit melanoma: the role of alkylating-agent resistance in regional therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02656730701805520

Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02656730701805520

Limb salvage with isolated perfusion for soft tissue sarcoma: could less TNF-alpha be better?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02656730701805520

Vascular complications of isolated limb perfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02656730701805520

The palliative value of tumor necrosis factor alpha-based isolated limb perfusion in patients with metastatic sarcoma and melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02656730701805520

Hyperthermic isolated limb perfusion (HILP) in malignant melanoma. Experience with 101 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02656730701805520

Long-term morbidity after regional isolated perfusion with melphalan for melanoma of the limbs. The influence of acute regional toxic reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02656730701805520

Functional morbidity after regional isolated perfusion of the limb for melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02656730701805520

Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02656730701805520

Reporting results of cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02656730701805520

Systemic toxicity after isolated limb perfusion with melphalan for melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02656730701805520

High plasma tumor necrosis factor (TNF)-alpha concentrations and a sepsis-like syndrome in patients undergoing hyperthermic isolated limb perfusion with recombinant TNF-alpha, interferon-gamma, and melphalan

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02656730701805520

Isolated limb perfusions with tumor necrosis factor and melphalan for locally recurrent soft tissue sarcoma in previously irradiated limbs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02656730701805520

Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02656730701805520

Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02656730701805520

Anaphylactoid reactions to protamine: an often lethal complication in insulin-dependent diabetic patients undergoing vascular surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02656730701805520

One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-transit metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02656730701805520

TNF dose reduction in isolated limb perfusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02656730701805520

Phase I-II study on isolation antiblastic fotemustine perfusion after dacarbazine chemosensitization for advanced melanoma of the extremities

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02656730701805520

Hyperthermic Isolated Perfusion With Low-Dose Tumor Necrosis Factor α and Doxorubicin for the Treatment of Limb-Threatening Soft Tissue Sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02656730701805520

10.1080/02656730701805520

21 January 2018

Identifiers

DOI

1 reference

18 August 2017

1 reference